Section Arrow
Quote
PBLS.NASDAQ
- Parabilis Medicines Inc
Quotes are at least 15-min delayed:2026/08/01 11:07 EDT
Regular Hours
Last
 33.98
+1.7 (+5.27%)
Day High 
34.18 
Prev. Close
32.28 
1-M High
33.65 
Volume 
356.15K 
Bid
33.3
Ask
53.74
Day Low
31.5 
Open
32.44 
1-M Low
26.42 
Market Cap 
3.95B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 30.96 
20-SMA 30.51 
50-SMA -- 
52-W High 34.4706 
52-W Low 24.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.77/--
Enterprise Value
3.99B
Balance Sheet
Book Value Per Share
-4.66
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
REPLReplimune Group11.2+5.79+107.02%-- 
GOSSGossamer Bio0.1695-0.0088-4.94%-- 
JUNSJupiter Neurosciences Inc0.09-0.0075-7.69%-- 
KPTIKaryopharm Therapeutics Inc.1.92-5.09-72.61%-- 
IOVAIovance Biotherapeutics4.07-0.62-13.22%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helicalpeptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between -catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.